NEFM (neurofilament, medium polypeptide) is an abundant intermediate filament (IF) protein in post-mitotic neurons. It is mapped to human chromosome 8q21. It is abundantly present in the nervous system. In human, the protein has 13 carboxy-terminal domains with phosphorylation sites.
Synonyms: Anti-160 kDa neurofilament protein; Anti-NEF3 antibody produced in rabbit; Anti-NF-M; Anti-Neurofilament 3; Anti-Neurofilament medium polypeptide; Anti-Neurofilament triplet M protein
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: NEFM (neurofilament, medium polypeptide) protein is involved in the axonal transport and neuronal cell apoptosis. Phosphorylation of NEFM allows the association between NEFM and microtubules. Deregulated phosphorylation of NEFM is associated with Alzheimer disease (AD). From gene mutation analysis, it has been predicted that NEFM may act as a susceptibility factor for the Parkinson's disease (PD).
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC